Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vital Therapies seeks $86.25m for cell therapy via artificial liver

This article was originally published in Clinica

Executive Summary

Vital Therapies said in September that a multi-tranche $76m venture funding commitment would fund the Phase III program for its human allogeneic cellular therapy for the treatment of acute liver failure (www.clinica.co.uk, 1 October 2012). Now the San Diego-based company is seeking up to $86.25m in an initial public offering to complete three late-stage clinical trials for its stem cell-based, bio-artificial liver therapy called ELAD.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT100963

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel